medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.medsovet-6192Research ArticleСОБЫТИЯEVENTSБлицкриг в терапии псориаза: эксперты обсудили выбор первого биологического препаратаBlitzkrieg in psoriasis therapy: experts discussed the choice of the first biological drugредакционнаястатьяEditorialArticle20210406202108710Copyright © редакционная с., 20212021редакционная с.Editorial a.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/6192

17  марта в  рамках 14-го Международного форума дерматовенерологов и  косметологов IFDC 2021  прошел сателлитный симпозиум на тему «Выбор первого биологического препарата в терапии псориаза». Эксперты в сфере здравоохранения и экономики обсудили критерии назначения генно- инженерных препаратов, а также фармакоэкономические и социальные проблемы терапии заболевания в современной России. 

.

ReferencesLangley R.G., Elewski B.E., Lebwohl M., Reich K., Griffiths C.E., Papp K. et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi: 10.1056/NEJMoa1314258.Langley R.G., Elewski B.E., Lebwohl M., Reich K., Griffiths C.E., Papp K. et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi: 10.1056/NEJMoa1314258.Blauvelt A., Gooderham M., Iversen L., Ball S., Zhang L., Agada N.O., Reich K. Efficacy and safety of ixekizumab for the treatment of moderateto- severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017;77(5):855–862. doi: 10.1016/j.jaad.2017.06.153.Blauvelt A., Gooderham M., Iversen L., Ball S., Zhang L., Agada N.O., Reich K. Efficacy and safety of ixekizumab for the treatment of moderateto- severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017;77(5):855–862. doi: 10.1016/j.jaad.2017.06.153.Al-Salama Z.T., Scott L.J. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis. Am J Clin Dermatol. 2018;19(6):907–918. doi: 10.1007/ s40257-018-0406-1.Al-Salama Z.T., Scott L.J. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis. Am J Clin Dermatol. 2018;19(6):907–918. doi: 10.1007/ s40257-018-0406-1.Machado Á., Torres T. Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date. Psoriasis (Auckl). 2018;8:83–92. doi: 10.2147/PTT.S165943.Machado Á., Torres T. Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date. Psoriasis (Auckl). 2018;8:83–92. doi: 10.2147/PTT.S165943.Papp K.A., Langley R.G., Lebwohl M., Krueger G.G., Szapary P., Yeilding N. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684. doi: 10.1016/S0140-6736(08)60726-6.Papp K.A., Langley R.G., Lebwohl M., Krueger G.G., Szapary P., Yeilding N. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684. doi: 10.1016/S0140-6736(08)60726-6.Gordon K.B., Langley R.G., Leonardi C., Toth D., Menter M.A., Kang S. et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598–606. doi: 10.1016/j. jaad.2006.05.027.Gordon K.B., Langley R.G., Leonardi C., Toth D., Menter M.A., Kang S. et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598–606. doi: 10.1016/j. jaad.2006.05.027.Лила А.М., Древаль Р.О., Шипицын В.В. Оценка организации медицинской помощи и лекарственного обеспечения при ревматических заболеваниях и социально-экономического бремени этих болезней в Российской Федерации. Современная ревматология. 2018;12(3): 112–119. doi: 10.14412/1996-7012-2018-3-112-119.Lila A.M., Dreval R.О., Shipitsyn V.V. Assessment of organization of medical care and drug provision for patients with rheumatic diseases, and the socioeconomic burden of these diseases in the Russian Federation. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(3):112–119. (In Russ.) doi: 10.14412/1996-7012-2018-3-112-119Gossec L., Baraliakos X., Kerschbaumer A., de Wit M., McInnes I., Dougados M. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712. doi: 10.1136/annrheumdis-2020-217159.Gossec L., Baraliakos X., Kerschbaumer A., de Wit M., McInnes I., Dougados M. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712. doi: 10.1136/annrheumdis-2020-217159.

The authors declare that there are no conflicts of interest present.